	US 11,692,967 B2
	Gel electrophoresis diagnostic kit and methods of using the same
Mounir A. Koussa, Kitchener (CA); Calvin Domenico, Herndon, VA (US); Ronald L. Green, Bethel, CT (US); Joshua John Forman, Winchester, MA (US); Andrew Ward, Everett, MA (US); and Lisa Caldwell, Westford, MA (US)
Assigned to Vital Biosciences Inc., Kitchener (CA)
Filed by Vital Biosciences, Inc., Kitchener (CA)
Filed on Sep. 29, 2020, as Appl. No. 17/36,076.
Application 17/036,076 is a continuation of application No. 16/321,723, granted, now 10,823,699, previously published as PCT/US2017/044544, filed on Jul. 28, 2017.
Claims priority of provisional application 62/452,429, filed on Jan. 31, 2017.
Claims priority of provisional application 62/368,635, filed on Jul. 29, 2016.
Prior Publication US 2021/0025848 A1, Jan. 28, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 27/453 (2006.01); G01N 33/561 (2006.01); G01N 27/447 (2006.01)

CPC G01N 27/453 (2013.01) [G01N 27/44743 (2013.01); G01N 33/561 (2013.01)]

20 Claims

1. A biomarker detector cartridge comprising:

a cartridge body;

a bodily fluid collector associated with the cartridge body and configured to receive a bodily fluid;

a nanoswitch source configured to be contacted by the fluid and comprising a plurality of nanoswitches of at least one type that bind at least one biomarker when the at least one biomarker is present in the fluid to thereby create biomarker-bound nanoswitches; and

an electrophoretic cell associated with the cartridge body and comprising a separation medium configured to allow electrophoretic separation of the biomarker-bound nanoswitches and unbound nanoswitches of the plurality of nanoswitches;

wherein the nanoswitch source is configured to release the plurality of nanoswitches into the fluid when the nanoswitch source is contacted by the fluid; or

wherein the cartridge body comprises an assay portion and a sample portion that are separated by a removable barrier; or

wherein the removable barrier encapsulates the separation medium and the removable barrier is configured to be removed to thereby allow the separation medium be used to allow the electrophoretic separation; or

wherein the plurality of nanoswitches are in a dry form before the fluid is received by the bodily fluid collector, and wherein the removable barrier is configured to maintain a moisture or solvent level at the separation medium and maintain the nanoswitch source in the dry form before the fluid is received by the bodily fluid collector; or

wherein the biomarker comprises one or more of a disease biomarker, an inflammation biomarker, a reproduction biomarker, and an aging biomarker; or

wherein the reproduction biomarker comprises one or more of an ovulation biomarker, a fertilization biomarker, an implantation biomarker, and an embryo development biomarker; or

wherein the biomarker comprises luteinizing hormone (LH) and Chorionic Gonadotropin (β-hCG); or

wherein the biomarker detector cartridge further comprises at least partially removable cap that is configured to compress the fluid collector after the fluid is received to thereby direct the received fluid to the electrophoretic cell; or

wherein the nanoswitch source comprises a sticker, a capsule, a pellet, or a residue; or

wherein the biomarker detector cartridge comprises a test result indicator coupled to the electrophoretic cell; or

wherein the separation medium comprises a dye that is capable of visualizing at least one of the plurality of nanoswitches; or

wherein the biomarker detector comprises a transfer portion comprising one or more applicators, wherein the transfer portion is in fluid communication with electrophoretic cell; or

wherein each of the one or more applicators is associated with a corresponding testing lane on the separation medium of the electrophoretic cell; or

wherein the electrophoretic cell comprises electrical contacts configured to couple to a power source, wherein the power source is optionally disposed within the biomarker detector cartridge.